BrightInsight Named to 2020 CB Insights Digital Health 150 - List of Most Innovative Digital Health Startups

I’m pleased to share that BrightInsight was named to the 2020 CB Insights Digital Health 150, an annual list of the most promising private digital health companies in the world. CB Insights is a leading market intelligence firm whose insights are well-respected and trusted across industries, making this recognition truly an honor.

The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. The Digital Health 150 companies span the globe, from Canada, China, Israel, France, the United Kingdom, and the United States, and have raised more than $20B in funding across 600+ deals from 900+ unique investors.

“This year’s Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more,” said CB Insights CEO Anand Sanwal. “Last year’s Digital Health 150 winners saw numerous exits and went on to raise nearly $5 billion in investor financing after being recognized. We look forward to seeing the success of this year's class of the best in digital health."

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum.

Quick facts on the 2020 Digital Health 150:

As digital health continues to proliferate, we are seeing significant adoption of our regulated BrightInsight Platform by the world’s top biopharma and medtech companies, including AstraZeneca, CSL Behring, Novo Nordisk and Roche. We owe much of our success to our innovative customers who have partnered with our team to build and host their transformational digital health solutions on top of our security-, regulatory- and privacy-compliant infrastructure.

I am incredibly proud of the BrightInsight team for this latest recognition on the heels of our Series B financing and look forward to sharing more exciting updates during the back half of 2020.

Back to Blog